WO2008094909A3 - Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions - Google Patents

Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions Download PDF

Info

Publication number
WO2008094909A3
WO2008094909A3 PCT/US2008/052315 US2008052315W WO2008094909A3 WO 2008094909 A3 WO2008094909 A3 WO 2008094909A3 US 2008052315 W US2008052315 W US 2008052315W WO 2008094909 A3 WO2008094909 A3 WO 2008094909A3
Authority
WO
WIPO (PCT)
Prior art keywords
conditions
sodium channel
mediated diseases
quinazolinone
pyrimidinone compounds
Prior art date
Application number
PCT/US2008/052315
Other languages
French (fr)
Other versions
WO2008094909A2 (en
Inventor
Shifeng Liu
Jianyu Sun
Robert Fraser
Jianmin Fu
Rajender Kamboj
Duanjie Hou
Serguei Sviridov
Original Assignee
Xenon Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc. filed Critical Xenon Pharmaceuticals Inc.
Publication of WO2008094909A2 publication Critical patent/WO2008094909A2/en
Publication of WO2008094909A3 publication Critical patent/WO2008094909A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is directed to compounds of formula (I): wherein (A), n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
PCT/US2008/052315 2007-01-29 2008-01-29 Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions WO2008094909A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88712007P 2007-01-29 2007-01-29
US60/887,120 2007-01-29
US89118807P 2007-02-22 2007-02-22
US60/891,188 2007-02-22

Publications (2)

Publication Number Publication Date
WO2008094909A2 WO2008094909A2 (en) 2008-08-07
WO2008094909A3 true WO2008094909A3 (en) 2010-03-11

Family

ID=39400881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/052315 WO2008094909A2 (en) 2007-01-29 2008-01-29 Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions

Country Status (4)

Country Link
AR (1) AR065081A1 (en)
CL (1) CL2008000252A1 (en)
TW (1) TW200836743A (en)
WO (1) WO2008094909A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403782B2 (en) 2011-05-10 2016-08-02 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
AU2009282480B2 (en) * 2008-08-11 2015-05-07 Children's Medical Center Corporation Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
WO2010026177A1 (en) * 2008-09-05 2010-03-11 Neurosearch A/S 1,4-diaza-bicyclo [3.2.2] nonyl pyridine derivatives as nicotinic and monoamine receptor modulators
AU2010204106B2 (en) * 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
SG174398A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Furopyrimidinedione derivatives as trpa1 modulators
PL2411393T3 (en) 2009-03-23 2014-06-30 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as trpa1 modulators
WO2010109328A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
SI2464645T1 (en) 2009-07-27 2017-10-30 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
EP2540728B1 (en) 2010-02-17 2019-04-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
US8703759B2 (en) 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
MX2013014679A (en) 2011-06-13 2014-07-14 Glenmark Pharmaceuticals Sa Treatment of respiratory disorders using trpa1 antagonists.
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
US20140107113A1 (en) 2011-06-22 2014-04-17 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
TW201837023A (en) 2011-07-01 2018-10-16 美商基利科學股份有限公司 Fused heterocyclic compounds as ion channel modulators
NO3175985T3 (en) 2011-07-01 2018-04-28
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
US20140364445A1 (en) 2011-12-05 2014-12-11 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
AU2013207796B2 (en) 2012-01-13 2017-04-27 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MY165622A (en) 2012-06-08 2018-04-18 Glenmark Pharmaceuticals Sa Amides of 2-amino-4aryl thiazole compounds and their salts
WO2014093869A1 (en) 2012-12-13 2014-06-19 University Of Kansas 6-substituted quinazolinone inhibitors
MA38661A1 (en) 2013-06-27 2017-03-31 Pfizer Heteroaromatic compounds and their use as d1 dopamine ligands
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (en) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
CA2926389A1 (en) 2013-10-15 2015-04-23 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20190175599A1 (en) 2014-09-16 2019-06-13 Glemark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
AR103297A1 (en) 2014-12-30 2017-05-03 Forma Therapeutics Inc PIRROLO AND PIRAZOLOPIRIMIDINAS AS INHIBITORS OF THE SPECIFIC PROTEASE 7 OF UBIQUITINA
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
JP2018504431A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Thienopyrimidinone as a ubiquitin-specific protease 7 inhibitor
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
CA3008171A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN111032662A (en) 2017-06-21 2020-04-17 尚医治疗有限责任公司 Compounds interacting with the RAS superfamily for the treatment of cancer, inflammatory diseases, RAS proteinopathies and fibrotic diseases
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
WO2020261114A1 (en) * 2019-06-27 2020-12-30 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
CN111018793A (en) * 2019-12-10 2020-04-17 深圳市易瑞生物技术股份有限公司 Hypnone hapten as well as synthesis method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3047462A (en) * 1959-03-06 1962-07-31 Lab Jacques Logeais Soc D Expl Quinazolone anti-inflammatory composition
US3458513A (en) * 1967-11-02 1969-07-29 Wallace & Tiernan Inc 2-substituted-tetrahydro-halosulfamyl-quinazolinones
US3721671A (en) * 1967-01-23 1973-03-20 Sumitomo Chemical Co Novel quinazolinone derivatives 2-alkyl-3-(3'-methylpyridine-2'-yl)-5-chloro-4(3h)-quinazolinone
DE2731299A1 (en) * 1976-07-14 1978-01-19 Science Union & Cie 4- (QUINAZOLINYL) -N-ARALKYL-PIPERIDINE, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
WO2004013111A1 (en) * 2002-08-01 2004-02-12 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3047462A (en) * 1959-03-06 1962-07-31 Lab Jacques Logeais Soc D Expl Quinazolone anti-inflammatory composition
US3721671A (en) * 1967-01-23 1973-03-20 Sumitomo Chemical Co Novel quinazolinone derivatives 2-alkyl-3-(3'-methylpyridine-2'-yl)-5-chloro-4(3h)-quinazolinone
US3458513A (en) * 1967-11-02 1969-07-29 Wallace & Tiernan Inc 2-substituted-tetrahydro-halosulfamyl-quinazolinones
DE2731299A1 (en) * 1976-07-14 1978-01-19 Science Union & Cie 4- (QUINAZOLINYL) -N-ARALKYL-PIPERIDINE, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
WO2004013111A1 (en) * 2002-08-01 2004-02-12 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAKER ET AL.: "An antimalarial alkaloid from Hydrangea. IV. Functional derivatives of 3-alkyl-4-quinazolones", JOURNAL OF ORGANIC CHEMISTRY, vol. 17, no. 1, 1952, pages 35 - 51, XP002548400 *
BOGERT M T ET AL: "RESEARCHES ON QUINAZOLINES (TWENTY-SEVENTH PAPER). THE SYNTHESIS OF 3-AMINOARYL-4-QUINAZOLONES FROM ACYLANTHRANILS AND AROMATIC DIAMINES", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC. US, vol. 33, 1 January 1911 (1911-01-01), pages 949 - 962, XP002453809, ISSN: 0002-7863 *
GRIMMEL ET AL.: "New Synthesis of 4-Quinazolones", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 68, 1946, pages 542 - 543, XP002547242 *
SHINGO ET AL.: "Efficient Solid Phase Synthesis of Diverse Quinazolinones", SYNLETT, no. 11, 2000, pages 1670 - 1672, XP002547139 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403782B2 (en) 2011-05-10 2016-08-02 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators

Also Published As

Publication number Publication date
WO2008094909A2 (en) 2008-08-07
CL2008000252A1 (en) 2008-03-14
AR065081A1 (en) 2009-05-13
TW200836743A (en) 2008-09-16

Similar Documents

Publication Publication Date Title
WO2008094909A3 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
MX2009008338A (en) Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions.
WO2008147864A3 (en) Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
WO2010045251A3 (en) Spiro-oxindole compounds and their use as therapeutic agents
MX2009003874A (en) Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents.
WO2008046087A3 (en) Spiro compounds and their uses as therapeutic agents
MY145694A (en) Spiroheterocyclic compounds and their uses as therapeutic agents
WO2008046084A3 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
WO2008151288A3 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MY167135A (en) Fused heterocyclic derivatives and methods of use
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
TW200720277A (en) Spiro-oxindole compounds and their uses as therapeutic agents
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
TW200716596A (en) Substituted amide derivatives and methods of use
WO2004005279A3 (en) Substituted anthranilic amide derivatives and methods of use
WO2008115999A8 (en) Biaryl and biheteroaryl compounds useful in treating iron disorders
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
WO2008109856A3 (en) Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2010132352A3 (en) Spiro compounds and their use as therapeutic agents
MX2009011059A (en) Aminopyrimidines useful as kinase inhibitors.
MX2009009466A (en) Tricyclic compounds useful in treating iron disorders.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08728467

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08728467

Country of ref document: EP

Kind code of ref document: A2